Ge Long Hui·2026-03-31 15:34Core Viewpoints - In 2025, the company achieved operating revenue of 575.168 billion yuan, a year-on-year decrease of 1.6%, and a net profit attributable to shareholders of 7.155 billion yuan, a year-on-year increase of 1.5%, aligning with previous expectations [1] - Looking ahead to 2026, the demand for in-hospital medications is expected to continue to grow, with stable revenue growth anticipated in the pharmaceutical distribution business, and rapid growth in the medical device distribution sector supported by projects like SPD [1][3] Event Summary - The company released its 2025 performance report, confirming that the results met prior expectations with operating revenue of 575.168 billion yuan and a net profit of 7.155 billion yuan [1] - China National Pharmaceutical Group proposed a final dividend of 0.69 yuan per share for the 2025 fiscal year, pending approval from the shareholders' meeting [1] Pharmaceutical Distribution Trends - In 2025, the pharmaceutical distribution segment's revenue decreased by 2.0% to 435.39 billion yuan, with a slight decline in operating profit margin [2] - Key regions such as East and North China maintained stable growth, while South China remained flat, with the company optimizing product categories and channel management to enhance market share [2] Medical Device Distribution - The medical device distribution segment's revenue also fell by 2.0% to 115.538 billion yuan, but the decline was less severe than in the first half of the year [2] - The company added 72 new SPD projects and 68 new centralized delivery projects, leading to double-digit growth in revenue from these initiatives [2] Retail Sector Performance - The retail segment saw a revenue increase of 6.67% to 38.383 billion yuan, with an improvement in operating profit margin [2] - The total number of retail pharmacies decreased to 9,682, with a notable increase in sales from specialized pharmacies due to policy support for innovative drugs [2] Profitability Outlook - For 2026, the company expects to see a return to stable growth in the pharmaceutical distribution sector, with the medical device segment benefiting from a recovery in large medical equipment tenders [3] - Continuous improvement in operational efficiency and cost reduction initiatives are anticipated to enhance profitability [3] Financial Metrics - The overall gross margin for 2025 was 7.25%, down by 0.32 percentage points, attributed to a decrease in the proportion of high-margin business [4] - The net cash flow from operating activities was 14.138 billion yuan, an increase from the previous year, indicating effective cash collection [4] Revenue and Profit Forecast - Projected revenues for 2026-2028 are 604.788 billion yuan, 637.024 billion yuan, and 671.348 billion yuan, with corresponding net profits of 7.678 billion yuan, 8.316 billion yuan, and 9.040 billion yuan [4]